Instill Intrapleural Tissue Plasminogen Activator (tPA) and DNase
The best next step is to instill intrapleural tissue plasminogen activator (tPA) and DNase into the existing pigtail catheter to address the persistent loculated empyema. This patient has a multiloculated empyema with ongoing sepsis despite appropriate antibiotics and partial drainage, requiring escalation of drainage therapy before considering surgical intervention.
Rationale for Fibrinolytic Therapy
The American Association for Thoracic Surgery (AATS) guidelines recommend a stepwise approach to empyema management, with VATS as first-line surgical therapy 1. However, this patient is an extremely poor surgical candidate given:
- Severe cardiac dysfunction (EF 25%) with high perioperative mortality risk
- Active stage IIIb lung cancer on chemotherapy
- Severe COPD requiring continuous oxygen
- Frail, cachectic state suggesting poor physiologic reserve
Intrapleural fibrinolytic therapy with tPA/DNase combination represents the appropriate next escalation before surgery 2. This approach is specifically designed for multiloculated effusions that fail initial chest tube drainage. The combination therapy has become standard practice for complicated parapneumonic effusions when small-bore chest tubes achieve only partial drainage 2.
Why Not the Other Options?
Changing to Meropenem
The organism is pansensitive E. coli, and ceftriaxone provides excellent coverage 3. Ceftriaxone achieves therapeutic levels in empyemic pleural fluid 4. The persistent fever and leukocytosis are due to inadequate drainage of loculated pockets, not antibiotic resistance. Changing antibiotics would not address the mechanical problem of undrained infected fluid 3.
Additional Pigtail Chest Tubes
While multiple tubes can be placed, the primary issue is loculation preventing drainage, not insufficient tube number. Adding more tubes without addressing the fibrinous septations is unlikely to succeed and increases procedural risk in this frail patient.
VATS with Decortication
This is the definitive surgical approach recommended by AATS guidelines 1, but this patient's prohibitive surgical risk makes VATS premature. The guidelines acknowledge that decortication requires patients who are "medically operable to tolerate major thoracic surgery" 1. With EF 25%, active cancer, severe COPD, and cachexia, his perioperative mortality would be extremely high. Surgery should be reserved for failure of less invasive measures.
Implementation Strategy
Administer tPA/DNase combination through the existing pigtail catheter using standard protocols (typically tPA 10 mg + DNase 5 mg twice daily for 3 days) 2
Continue ceftriaxone at appropriate dosing for the pansensitive E. coli 3
Monitor clinical response over 48-72 hours:
- Temperature trends
- Leukocyte count
- Chest imaging to assess drainage
- Pleural fluid output
If fibrinolytic therapy fails (persistent fever, leukocytosis, or imaging shows inadequate drainage after 3-5 days), then reassess surgical candidacy with multidisciplinary input including cardiology, oncology, and thoracic surgery
Critical Caveats
The prognosis remains guarded given the combination of severe comorbidities 5. Even with optimal empyema management, his underlying conditions (advanced cancer, severe heart failure) portend poor long-term outcomes.
Fibrinolytic therapy has a 45% failure rate in some series, particularly when pleural peel is present 6. However, CT findings of multiloculation alone do not predict failure—pleural peel does 6.
Close monitoring for complications of fibrinolytics (bleeding, though rare with intrapleural administration) is essential given his multiple comorbidities.
Goals of care discussion should occur concurrently, as this patient may not be a candidate for aggressive surgical intervention even if fibrinolytics fail 5.
The stepwise approach—optimizing drainage with fibrinolytics before considering surgery—respects both evidence-based guidelines and this patient's limited physiologic reserve 1, 2.